Company profile for jCyte

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At jCyte, we are committed to developing an effective stem cell therapy for retinitis pigmentosa (RP) and bringing it quickly to patients. The need is great. There are no medical treatments for RP. To change that, Drs. Henry Klassen and Jing Yang have spent decades in the lab, investigating the mechanisms that drive RP and other retinal diseases. Their work led them to retinal progenitor cells (RPCs), a type of stem cell that...
At jCyte, we are committed to developing an effective stem cell therapy for retinitis pigmentosa (RP) and bringing it quickly to patients. The need is great. There are no medical treatments for RP. To change that, Drs. Henry Klassen and Jing Yang have spent decades in the lab, investigating the mechanisms that drive RP and other retinal diseases. Their work led them to retinal progenitor cells (RPCs), a type of stem cell that can only become retinal cells. Over time, Drs. Klassen and Yang learned to produce quality RPCs in large batches. In pre-clinical studies, they showed these cells could rescue, and even replace diseased retinal cells.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1000 Newport Center Drive, 231 Newport Beach, CA 92660
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2025-08-25/jcyte-announces-publication-of-phase-iiia-safety-study-of-retinal-progenitor-cells-in-retinitis-pig

PHARMAWEB
25 Aug 2025

https://www.businesswire.com/news/home/20250818947550/en/jCyte-Inc.-Announces-First-Patients-Treated-in-JC02-88-Trial-for-Retinitis-Pigmentosa

BUSINESSWIRE
18 Aug 2025

https://www.businesswire.com/news/home/20240221325698/en

BUSINESSWIRE
21 Feb 2024

https://www.contractpharma.com/contents/view_breaking-news/2022-09-29/center-for-breakthrough-medicines-and-jcyte-ink-manufacturing-deal/9769

CONTRACTPHARMA
29 Sep 2022

https://www.prnewswire.com/news-releases/center-for-breakthrough-medicines-cbm-and-jcyte-announce-strategic-partnership-to-manufacture-jcytes-innovative-cell-therapy-for-treatment-of-retinal-degenerative-diseases-301628588.html

PRNEWSWIRE
20 Sep 2022

https://www.businesswire.com/news/home/20220712005263/en

BUSINESSWIRE
12 Jul 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty